VERNON HILLS, Ill.--(BUSINESS WIRE)--Biopharmaceutical company Applied NeuroSolutions, Inc. (OTCBB:APNS)(www.appliedneurosolutions.com)
today announced Dutton Associates, an independent research organization,
upgraded its recommendation of the Company’s
stock to “Strong Speculative Buy”
from “Speculative Buy”
and raised its 12-month price target to $1.00 a share from $0.50 a share.
In a research note, Dutton Associates noted that Applied NeuroSolutions’
agreement with Eli Lilly and Company (NYSE:LLY), to develop therapeutics
to treat Alzheimer’s disease, was the reason
behind the upgraded rating and price target increase. The research note
is available on the Dutton Associates web site at www.DuttonAssociates.com.
About Applied NeuroSolutions:
Applied NeuroSolutions, Inc. (OTCBB:APNS) is developing novel
therapeutic compounds to treat and diagnostics to detect Alzheimer's
disease based on discoveries originating from the Albert Einstein
College of Medicine. Applied NeuroSolutions has discovered biomarkers
that the company believes will aid in the development of effective AD
treatments. Applied NeuroSolutions has also been working on both a
cerebrospinal fluid (CSF) test and a blood test to detect AD at a very
early stage. This test can also differentiate AD patients from those
with other diseases that have similar symptoms. There is currently no
FDA approved diagnostic test to detect Alzheimer's disease. Alzheimer's
disease currently afflicts over 4 million Americans, and the market for
AD therapy is expected to grow to 21 million patients by 2010 in the
seven major pharmaceutical markets (USA, France, Germany, Italy, Spain,
U.K. and Japan) according to BioPortfolio, Ltd. For more information,
visit www.appliedneurosolutions.com.
This press release contains forward-looking statements about Applied
NeuroSolutions. The company wishes to caution the readers of this press
release that actual results may differ from those discussed in the
forward-looking statements and may be adversely affected by, among other
things, the risks associated with new product development and
commercialization, clinical trials, intellectual property, regulatory
approvals, potential competitive offerings, and access to capital. For
further information, please visit the company's website at www.appliedneurosolutions.com,
and review the company's filings with the Securities and Exchange
Commission.
